Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Hutchison

Orthopaedic Surgery Jackson, TN Medical Doctor

NPI 1215036843 CMS profile 190832

24 Physicians Dr, Jackson, TN 38305

Open in the dashboard

General payments

$61,348

179 records reported · program years 2019–2025

Research payments

$39,852

Paid to them · 13 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$204,622 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Jason Hutchison of Jackson, TN is reported in the CMS Open Payments database as having received $61,348 across 179 general payments and $39,852 in research payments paid to them. Separately, studies naming them as principal investigator received $204,622 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,540 20
2024 General $14,641 27
2024 Research $36,377 8
2023 General $2,322 19
2023 Research $3,475 5
2022 General $2,792 19
2021 General $7,751 16
2020 General $11,081 28
2019 General $20,221 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Hutchison
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Jason Hutchison were reported at $2,540. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Jason Hutchison Orthopaedic Surgery median Middle half National median
2019 $20,221 $644 $140–$2,844 $163
2020 $11,081 $312 $75–$1,860 $114
2021 $7,751 $520 $117–$2,495 $132
2022 $2,792 $598 $128–$2,731 $149
2023 $2,322 $461 $128–$2,264 $160
2024 $14,641 $497 $134–$2,475 $164
2025 $2,540 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $57,956 104 payments
  2. DeRoyal Industries, Inc. $737 3 payments
  3. Aesculap Biologics, LLC $445 6 payments
  4. DePuy Synthes Sales Inc. $345 8 payments
  5. Vericel Corporation $245 6 payments
  6. Onkos Surgical, Inc. $161 1 payment
  7. Sonex Health, Inc. $131 1 payment
  8. Vertex Pharmaceuticals Incorporated $125 5 payments
  9. Wright Medical Technology, Inc. $118 2 payments
  10. Medical Device Business Services, Inc. $117 1 payment
  11. Other $969 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $26,580 15 payments
  2. Consulting Fee $19,624 12 payments
  3. Travel and Lodging $8,380 26 payments
  4. Food and Beverage $6,169 124 payments
  5. Entertainment $595 2 payments
Products named General payments · program years 2019–2025
  1. REAL INTELLIGENCE $18,969 28 payments
  2. Navio Surgical System $15,707 27 payments
  3. JOURNEY II Recon Knees $8,173 10 payments
  4. NAVIO $7,658 13 payments
  5. RI Hip Navigation $6,065 13 payments
  6. JOURNEY II Recon Knees $5,593 12 payments
  7. POLARSTEM $3,905 5 payments
  8. Journey PFJ $3,850 3 payments
  9. Journey II BCS $3,738 9 payments
  10. OR3O $3,527 4 payments
  11. Other $39,496 164 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Episurf Medical, Inc. $39,852 13 payments

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

327

Median for Orthopedic Surgery: 203

Drug cost

$1,878

Median for Orthopedic Surgery: $1,433

Branded share of claims

47.1%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 97 $612
Mupirocin Generic 77 $555
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 57 $438
Celecoxib Generic 22 $165
Tramadol Hcl Generic 32 $57
Meloxicam Generic 14 $27
Cephalexin Generic 28 $25

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 133 billing codes

Paid by Medicare

$275,774

Of which drugs: $18,413

Medicare patients

824

Average age 75

Services billed

14,567

513 women, 311 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 32%
Diabetes 30%
Depression 26%
Chronic kidney disease 23%
COPD 19%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 12 576 $7,500
Injection, methylprednisolone acetate, 1 mg J1010 Office 130 10,841 $1,054
Injection, methylprednisolone acetate, 80 mg J1040 Office 31 31 $206
Injection, methylprednisolone acetate, 40 mg J1030 Office 15 17 $81

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Exparel
  • Pacira Pharmaceuticals Incorporated $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

192 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record